Sarepta Therapeutics Inc (LTS:0L35)
$ 121.67 0 (0%) Market Cap: 11.61 Bil Enterprise Value: 11.80 Bil PE Ratio: 78.90 PB Ratio: 9.50 GF Score: 82/100

Sarepta Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 13, 2020 / 05:30PM GMT
Release Date Price: $132.04
Anupam Rama
JP Morgan Chase & Co, Research Division - VP and Analyst

Okay. We'll go ahead and get started.

Welcome, everyone, to the 2020 JP Morgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JP Morgan. I'm joined by Tessa Romero and Matt Bannon from the team. Our next presenting company is Sarepta, and presenting on behalf of the company is CEO, Doug Ingram. Doug?

Douglas S. Ingram
Sarepta Therapeutics, Inc. - President, CEO & Director

Thank you. Thank you, Anupam. And to those in the room and also on the web, thank you for joining Sarepta this morning. Before I begin, let me say that I'll be making some forward-looking statements. Here is a laundry list of the various risks and uncertainties you may want to consider whenever one has the temerity to try to predict the future.

And with that, let's begin. So with the great advances that have occurred in genetic medicine, in 2018, Sarepta envisioned a revolution, and we built a strategy with the goal of being among the most

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot